Lin BioScience, Inc. (TPEX:6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
161.00
0.00 (0.00%)
Aug 15, 2025, 2:59 PM CST
75.19%
Market Cap 13.32B
Revenue (ttm) n/a
Net Income (ttm) -744.27M
Shares Out 82.73M
EPS (ttm) -9.47
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 601,538
Average Volume 718,500
Open 161.00
Previous Close 161.00
Day's Range 159.00 - 164.00
52-Week Range 88.40 - 180.50
Beta -0.03
RSI 61.03
Earnings Date Aug 13, 2025

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.